Shanghai Henlius Biotech, Inc. Stock price

Equities

2696

CNE100003N76

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
13.62 HKD -1.73% Intraday chart for Shanghai Henlius Biotech, Inc. -4.35% -2.01%

Financials

Sales 2023 5.39B 747M 5.84B Sales 2024 * 5.89B 816M 6.38B Capitalization 6.96B 963M 7.53B
Net income 2023 546M 75.56M 591M Net income 2024 * 600M 83.04M 650M EV / Sales 2023 1.27 x
Net cash position 2023 * - 0 0 Net cash position 2024 * - 0 0 EV / Sales 2024 * 1.18 x
P/E ratio 2023
12.6 x
P/E ratio 2024 *
11.7 x
Employees 3,637
Yield 2023 *
-
Yield 2024 *
-
Free-Float 21.57%
More Fundamentals * Assessed data
Dynamic Chart
Shanghai Henlius Biotech Turns to Profit in 2023 MT
Shanghai Henlius Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Henlius Biotech Doses First Patient in Phase 1 Clinical Trial of Cancer Drug MT
Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection CI
Shanghai Henlius Biotech's Fibrosis Drug Gets Chinese Authorities' Nod for Clinical Trials MT
Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration CI
Shanghai Henlius Biotech Expects Record Full-Year Profit MT
Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2023 CI
Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration CI
Henlius Biotech Completes Phase 1 Clinical Study of Denosumab Biosimilar MT
Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed CI
Sermonix Pharmaceuticals Inc. and Shanghai Henlius Biotech, Inc. Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene CI
Henlius Biotech Renews Promotional Services Deal With Jiangsu Fosun Pharmaceutical Sales for the Marketing of Breast Cancer Drug MT
Indonesia Grants Marketing Approval to Henlius Biotech's Small-Cell Lung Cancer Treatment MT
Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration CI
More news
1 day-1.73%
1 week-4.35%
Current month+1.49%
1 month+3.18%
3 months-1.30%
6 months+26.11%
Current year-2.01%
More quotes
1 week
13.62
Extreme 13.62
14.38
1 month
12.98
Extreme 12.98
15.58
Current year
12.20
Extreme 12.2
15.58
1 year
9.60
Extreme 9.6
17.40
3 years
9.60
Extreme 9.6
46.45
5 years
9.60
Extreme 9.6
67.05
10 years
9.60
Extreme 9.6
67.05
More quotes
Managers TitleAgeSince
Founder - 09-11-30
Chief Executive Officer 46 21-11-29
President 56 20-09-30
Members of the board TitleAgeSince
Director/Board Member 51 13-01-14
Director/Board Member 54 19-09-01
Director/Board Member 53 18-12-23
More insiders
Date Price Change Volume
24-03-28 13.62 -1.73% 176 641
24-03-27 13.86 -0.72% 112,200
24-03-26 13.96 +0.43% 105,500
24-03-25 13.9 -1.84% 167,100
24-03-22 14.16 -0.56% 211,204

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company's main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
12.8 CNY
Average target price
16.39 CNY
Spread / Average Target
+27.99%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Shanghai Henlius Biotech, Inc. - Hong Kong S.E.